
Robert Allen, MD, on variant monitoring, antibody development, and the company's long-term approach to patient care.
Allen is the Chief Scientific Officer at Invivyd.

Robert Allen, MD, on variant monitoring, antibody development, and the company's long-term approach to patient care.

Robert Allen, PhD, discusses how Pemgarda’s stability in targeting the spike protein's receptor-binding domain offers crucial protection, including immunocompromised individuals.

Invivyd’s Chief Scientific Officer Robert Allen, PhD, discusses the company’s pemivibart (Pemgarda) including its administration, how it can be used in concert with vaccines, and how it protects against newer variants.

Published: October 21st 2024 | Updated:

Published: February 3rd 2025 | Updated: